World Endometriosis Society (WCE 2023)

No ORCID on file · 2 papers in corpus
article 2023
Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial

/

article 2023
World Endometriosis Society (WCE 2023)

"Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial"